Differential Effectiveness of Atypical Antipsychotics on Hallucinations

A Pragmatic Randomized Controlled Trial

Igne Sinkeviciute, MD,*†‡ Kenneth Hugdahl, PhD,*§ Christoffer Bartz-Johannessen, MS,*†† Rune Andres Kroken, MD, PhD,*†‡ Else-Marie Løberg, PhD,*†||‡‡ Eirik Kjelby, MD, PhD,*† Maria Anna Rettenbacher, MD, PhD,# Inge Joa, PhD,***†‡† Solveig Kleebo Reitan, MD,‡‡‡§§ Renata Alisauskiene, MD,*†‡ Fairivar Fathian, MD, PhD,*† and Erik Johnsen, MD, PhD**†‡

Abstract:
Background: Most studies investigating antipsychotic effectiveness report either total psychopathology or symptom cluster findings. Studies focusing on a separate symptom, such as hallucinations, a hallmark symptom in schizophrenia, are scarce. Therefore, the current study aims to compare the antihallucinatory effectiveness of 3 pharmacologically different antipsychotics: olanzapine, amisulpride, and aripiprazole.

Methods: The present study is part of the Bergen-Stavanger-Innsbruck-Trondheim study, a 12-month prospective, randomized, pragmatic antipsychotic drug trial in active-phase schizophrenia spectrum disorders. The primary outcome of the present study was change of hallucinations as measured by item P3 (hallucinatory behavior) from the Positive and Negative Syndrome Scale at baseline, indicating the presence of hallucinations (HALL subgroup).

Results: A total of 144 participants were included in the study, where 105 (72%) had a score of 3 or more on the Positive and Negative Syndrome Scale P3 item at baseline, indicating the presence of hallucinations (HALL subgroup).

Conclusions: A differential antihallucinatory effect of the 3 study drugs was present. The inferior effect of olanzapine seems to be driven by the subgroup of participants exposed to antipsychotic treatment before entering the study, antihallucinatory differences were revealed only in the latter group.

Key Words: antipsychotics, hallucinations, differential effectiveness, randomized trial

(J Clin Psychopharmacol 2021;41: 389–396)

Variability in the effectiveness of antipsychotic treatment remains a major clinical challenge in the treatment of schizophrenia-spectrum disorders.1 Whereas individually tailored drug protocols are established in other medical disciplines, antipsychotic treatment is much less targeted, with a trial-and-error approach often lasting from weeks to months and even years.2 The consequence of this trial-and-error approach may be long-term exposure to drugs without clear benefits and with possible risk of reinforcing adverse effects, prolonged suffering, and adverse impact on long-term prognosis because of sustained illness.3 Overall antipsychotic effectiveness is thoroughly documented.4 However, the focus in the majority of studies has been either change of total psychopathology or clusters of symptom scores.3,4 This might conceal effectiveness differences between separate symptoms of interest. Different symptoms might have, at least in part, separate underlying psychopathology5 and combining them might mask underlying differences. Because psychotic disorders are symptomatically heterogeneous, revealing possible differences among antipsychotics for separate symptoms would contribute to understanding symptom-specific and personalized treatment.6

Hallucinations are one of the hallmark symptoms of schizophrenia and related disorders. As much as 80% of patients experience hallucinations, where auditory hallucinations are reported most frequently.7 Hallucinations in general and auditory verbal hallucinations in particular are important treatment targets, being not only a major burden to patients but might also lead to self-harm, suicide, violence or homicide.8,9 Hallucinations respond well to...
Methods

Study Design

The present study is part of the Bergen-Stavanger-Innsbruck-Tromsö study (BeSt InTro; ClinicalTrials.org, number NCT01446328).

The BeSt InTro study aimed to compare 3 pharmacologically different antipsychotics—amisulpride, aripiprazole, and olanzapine—in a prospective, randomized, pragmatic design. The study was conducted between 2011 and 2017 at the Division of Psychiatry, at Haukeland University Hospital in Bergen, Stavanger University Hospital in Stavanger, St Olavs Hospital, Trondheim, and at the Medizinische Universität Innsbruck, Austria. The BeSt InTro study was funded by The Research Council of Norway, the Western Norway Regional Health Trust, and participating hospitals and universities and did not receive any financial or other support from the pharmaceutical industry. The study was approved in Norway by the Regional Committees for Medical and Health Research Ethics, and in Austria by the Ätiikommission der Medizinische Universität Innsbruck, and the Austrian Federal Office for Safety in Health Care (BASG). Further details can be found in the previous publication of the primary outcome. The data presented here represent secondary outcomes in the BeSt InTro trial.

Participants

A total of 144 participants aged ≥18 years with active psychosis symptoms as determined by a score of ≥4 on one or more of the following Positive and Negative Syndrome Scale (PANSS) items: P1 (delusions), P3 (hallucinatory behavior), P5 (grandiosity), P6 (suspiciousness/persecution) or G9 (unusual thought content) were included in the present study.

Participants were excluded if they were not able to use oral drugs, did not understand the native language, were hypersensitive to the active substances or to any of the excipients of the study drugs, and had prolactin-dependent tumors (eg, pituitary gland prolactinomas and breast cancer), pheochromocytoma in combination with medications that could induce torsade de pointes, and a known risk of narrow-angle glaucoma. All included participants had a diagnosis within the schizophrenia spectrum (F20–29) as defined in the International Classification of Disease, Tenth Revision. After participants signed an informed consent form, they were randomized to 1 of 3 study drugs. The descriptive statistics for the included participants at baseline are presented in Table 1.

Study Medications and Assessments

Each participant was offered a study drug based on a sealed, opaque envelope containing a list of the study drugs organized in a random sequence. The random sequences were prepared in advance by statisticians independent of the study. The first drug in the sequence was to be offered by the attending psychiatrist and defined the randomization drug. In the case of inability to use the first offered drug based on previous negative experience, the patient was offered the second one in the sequence, with the option to choose the third drug, if the second drug could not be used either. The distribution based on the first drug in the sequence (randomization drug) was amisulpride (n = 44), aripiprazole (n = 48), and olanzapine (n = 52).

The treating psychiatrist was free to determine dosing within the following ranges as defined by the following: amisulpride 50–1200 mg/d, aripiprazole 5–30 mg/d, and olanzapine 2.5–20 mg/d. The rationale was to allow the whole dose range for all study drugs to mimic everyday clinical circumstances and allow for up-titration and down-titration of doses based on the clinical presentation. The mean doses used with SDs were for amisulpride 396.9 (206.9) mg, aripiprazole 14.6 (7.0) mg, and olanzapine 12.3 (3.8) mg. The combination with other psychotropics, discontinuation, and any cross-titration between antipsychotics was left to the discretion of the treating psychiatrist. The use of additional psychotropic drugs was generally not different between the study drug groups. In case a participant already used an antipsychotic agent in therapeutic dosage (>0.5 defined daily dosages) at admission, no wash-out was carried out before starting on the study drug. This was the case in 28 patients at baseline, with the following distribution among the randomization groups: aripiprazole (n = 1), aripiprazole (n = 1), olanzapine (n = 1), and aripiprazole (n = 1) for the amisulpride randomization group; aripiprazole (n = 2), olanzapine (n = 4), aripiprazole (n = 4), and risperidone (n = 2) for the aripiprazole randomization group; and aripiprazole (n = 3), olanzapine (n = 1), and aripiprazole (n = 1) for the olanzapine randomization group (n = 3). In the 3 cases where the first drug in the randomization sequence was the same as the one the patient was already using, the next study drug in the sequence was chosen. The randomization was open to both the
The primary outcome of the present study was change of hallucinations as measured by item P3 (hallucinatory behavior) in the PANSS positive subscale. A score of 3 or higher indicated the presence of hallucinations.

Participants with hallucinations at baseline defined the hallucination (HALL) subgroup. Whereas a threshold of 3 serves as a cutoff for presence of hallucinations per se, a score of 4 or more indicates hallucinations where thinking and behavior are affected, that is, psychosis being present. Sensitivity analyses were therefore undertaken for those with a P3 score of 4 or higher. Although the comparisons between study drugs were unbalanced or biased, no previous exposure to antipsychotic drugs; CDSS, the Calgary Depression Scale for Schizophrenia; n, number in the total sample; n (%), number (percent) with characteristics; Smoking, daily tobacco smokers.

### Statistical Analyses

Statistical analyses were conducted according to intention-to-treat (ITT) and per-protocol (PP) groups. Intention-to-treat analysis is based on the first drug in the sequence, the randomization group, whereas PP analysis is based on which medication participants chose. The ITT analyses were defined as the primary analyses before the start of the trial, accompanied by secondary PP analyses, as both strategies have advantages and disadvantages. Intention-to-treat analyses have the main advantage of being unbiased because they are based on randomization groups. However, patients might choose another drug than the first one in the sequence. Thus, differences between the study drugs may be leveled out. The PP analyses have the main advantage of being based on the actually study drug chosen but have the disadvantage of potential selection bias, as the randomization is no longer valid. Thus, differences found between the study drugs may be biased.

Statistical analyses for the outcome variable were conducted in statistical program software R with a linear mixed-effects model (LME). The linear mixed-effects model is a preferred class of models when there are missing data because of its ability to handle both data that are missing completely at random and data that are missing at random. A random intercept was included in the model to account for intraindividual correlation, as each individual had repeated measurements for the outcome variable. The model was fitted to investigate the level of the outcome variable.

The analysis strategy was as follows: first, the analyses were conducted in the HALL subgroup after an initial analysis in the main group for the primary analyses in the present study.
whole sample. Second, analyses for the differences among study drugs in patients who were antipsychotic-naive (AP−) and patients who were exposed to antipsychotic treatment before entering the study (AP+) were conducted in the HALL subgroup. Third, the differences for AP− and AP+ subgroups were analyzed in each study drug, in the HALL subgroup. All steps were repeated in the sensitivity analysis for patients with baseline PANSS P3 ≥4.

RESULTS

The baseline mean P3 score for the total sample was 3.64 (0.13). Discontinuation of study drug during the treatment course and lost to follow-up rates are provided in Supplementary Material S1, http://links.lww.com/JCP/A751.

A total of 105 patients (71.9%) scored 3 or more on the PANSS P3 hallucinatory behavior item at baseline (HALL subgroup). The baseline ITT distribution of study drugs at the HALL subgroup was amisulpride (n = 33), aripiprazole (n = 33), and olanzapine (n = 39). The HALL subgroup was not substantially different from the total sample with regard to demographic or clinical descriptives, except for hallucinations. The descriptive statistics for the HALL subgroup are provided in Table 2.

Overall Analysis

Initially analyses were conducted in the whole sample to compare the study drugs on the main outcome measure P3.

No statistically significant differences among the 3 study drugs were seen for P3 score change in the ITT analysis, although a trend for statistically significant less reduction in the aripiprazole group compared with amisulpride was seen at week 3. Per-protocol analyses showed a lower baseline P3 score for the aripiprazole group compared with amisulpride was seen at week 3. Per-protocol analyses for the differences among study drugs in patients who were antipsychotic-naive (AP−) and patients who were exposed to antipsychotic treatment before entering the study (AP+) were conducted in the HALL subgroup. Third, the differences for AP− and AP+ subgroups were analyzed in each study drug, in the HALL subgroup. All steps were repeated in the sensitivity analysis for patients with baseline PANSS P3 ≥4.

| Table 2. PANSS P3 Mean Scores and SD for the Total Sample and for the HALL Subgroup |
|---------------------------------------------------------------|
| **Weeks** | **All Participants** | **HALL Subgroup** |
| **Baseline** | 3.64 (0.13) | 4.51 (0.14) |
| 1 | 3.01 (0.13) | 3.65 (0.14) |
| 3 | 2.53 (0.14) | 2.98 (0.15) |
| 6 | 2.21 (0.15) | 2.57 (0.15) |
| 12 | 2.17 (0.15) | 2.45 (0.16) |
| 26 | 1.9 (0.17) | 2.23 (0.18) |
| 39 | 1.82 (0.17) | 2.21 (0.18) |
| 52 | 1.78 (0.17) | 2.14 (0.19) |
Analyses for AP− and AP+ Participants

Only the HALL subgroup was chosen for further analyses. We used the same statistical analyses separately for AP− and AP+ participants. Similar results for the ITT and the PP analyses were seen in both subgroups. No differences among the 3 study drugs were found for the AP− participants (Supplementary Material S5; Tables S5–1, S5–2, http://links.lww.com/JCP/A751). In the AP+ subgroup, there were significant differences for the P3 score reduction between aripiprazole and amisulpride at week 3 for both the ITT and PP analyses (P = 0.043 and 0.012, respectively). No significant differences were seen at other time points. Olanzapine showed significantly less reduction in the P3 score when compared with amisulpride at weeks 12, 26, 39, and 52 (P = 0.001, 0.001, 0.002, and 0.023, respectively) in the ITT analysis and at weeks 3, 12, 26, and 39 (P = 0.041, 0.015, 0.004, and 0.020, respectively) in the PP analysis. Moreover, olanzapine showed less reduction in P3 score when compared with aripiprazole at weeks 12 and 26 (P = 0.040 and 0.009, respectively) in the ITT analysis and at week 12 (P = 0.007) in the PP analysis. Results for the ITT analysis are shown in Table 4 and for the PP analysis in Supplementary Material S6, http://links.lww.com/JCP/A751.

Analyses for Each Study Drug: AP+ Versus AP−

The same statistical approach was used for each study drug separately. No statistically significant differences were seen between the AP− and AP+ in participants who used amisulpride or aripiprazole, neither in the ITT nor in the PP analysis. For participants who used olanzapine, there was a significant difference in reduction of the P3 score between the AP− and AP+ subgroups at week 26 for both the ITT and the PP analyses (P = 0.034 and 0.022, respectively; Fig. 1). Furthermore, there was a significant difference at week 12 and a trend toward significance at week 39 in the PP analysis (P = 0.038 and 0.053, respectively; Supplementary Material S7; Tables S7-1, S7-2, http://links.lww.com/JCP/A751).

Sensitivity Analyses

We conducted a sensitivity analysis where patients with PANSS P3 score ≥4 were included following the same statistical approach. Similar results were found (Supplementary Material S8, http://links.lww.com/JCP/A751): in the total subgroup ITT analysis, olanzapine showed less reduction compared with amisulpride at weeks 12, 26, 39, and 52 (P = 0.004, 0.032, 0.025, and 0.02,

Table 4. ITT Analysis, HALL-Subgroup, AP+

|                | Baseline | 1 wk   | 3 wk   | 6 wk   | 12 wk  | 26 wk  | 39 wk  | 52 wk  |
|----------------|----------|--------|--------|--------|--------|--------|--------|--------|
| Amisulpride    | (n = 20) |        |        |        |        |        |        |        |
|                | 4.45 (0.296) | −0.89 (0.309) | −2.00 (0.309) | −2.47 (0.328) | −2.98 (0.345) | −2.99 (0.395) | −3.16 (0.38) | −2.93 (0.413) |
| Aripiprazole   | (n = 16) | [P = 0.908] | −0.64 (0.349) | −1.01 (0.358) | −2.05 (0.368) | −2.42 (0.408) | −2.68 (0.427) | −2.52 (0.512) | −2.56 (0.561) |
|                | [P = 0.599] | [P = 0.043] | [P = 0.41] | [P = 0.308] | [P = 0.611] | [P = 0.329] | [P = 0.599] |        |
| Olanzapine     | (n = 23) | [P = 0.476] | −0.6 (0.29) | −1.68 (0.296) | −1.73 (0.307) | −1.38 (0.314) | −1.2 (0.359) | −1.57 (0.333) | −1.69 (0.338) |
|                | [P = 0.499] | [P = 0.113] | [P = 0.113] | [P = 0.049] | [P = 0.009] | [P = 0.002] | [P = 0.023] |        |
|                | [P = 0.928] |         | [P = 0.164] | [P = 0.52] | [P = 0.049] | [P = 0.009] | [P = 0.124] | [P = 0.189] |        |

P values in bold correspond to statistical significant findings.
Numbers in the baseline column give the estimated values, and numbers in the other columns give the estimated decrease in PANSS P3 compared with baseline. Numbers in parentheses are estimated SDs. P values in single brackets correspond to comparison to the reference drug amisulpride. P values in double brackets correspond to comparison to aripiprazole.
respective; Table S8-1). Differences between olanzapine and aripiprazole were no longer significant, although a trend for less P3 score reduction for olanzapine in week 12 was observed (Table S8-1). In the PP analysis, there were no statistical significant differences (Table S8-2). As in the analyses based on a P3 score threshold ≥3, no statistically significant differences were found among antipsychotics for the AP− participants, neither in ITT nor in PP analyses (Tables S8-3, S8-4). For the AP+ participants, the ITT analysis revealed less reduction for olanzapine compared with amisulpride at weeks 12, 26, 39, and 52 (P = 0.001, 0.003, 0.025, 0.004, and 0.025, respectively) and less reduction for olanzapine compared with aripiprazole at week 26 (P = 0.021; Table S8-5). The PP analysis revealed less reduction in the olanzapine group compared with amisulpride at weeks 3, 12, and 26 (P = 0.037, 0.021, and 0.015, respectively) and less reduction in the olanzapine group compared with aripiprazole at week 12 (P = 0.01; Table S8-6). As in the separate analyses for P3 ≥ 3 of each study drug, statistically significant results were only found for olanzapine in the P3 ≥ 4 analyses. In the ITT analyses of olanzapine, the AP− participants had greater P3 score reductions than did AP+ participants in weeks 26 and 39 (P = 0.044 and 0.05). In the PP analyses, statistically significant differences were reached at weeks 12, 26, and 39 (P = 0.046, 0.031, and 0.024, respectively; Tables S8-7, S8-8).

**DISCUSSION**

The main objective of the study was to investigate differences in effectiveness among 3 pharmacologically different antipsychotics for reduction of hallucinations. The study showed differential effectiveness for participants who had used antipsychotics before entering the study, whereas no differences were seen in AP− participants. A faster decrease of hallucinations appeared in the amisulpride group at 3 weeks compared with aripiprazole in both the ITT and the PP analyses and to olanzapine in the PP analysis. The finding of earlier response to amisulpride might theoretically be biased by differences in the doses, as amisulpride is normally up-titrated more quickly than olanzapine. However, this was not the case in our study, where the olanzapine dose was in fact relatively higher than amisulpride and aripiprazole at 3 weeks.

The most consistent differences between the study drugs appeared later in the treatment.

The study shows that hallucinations in general respond well and rapidly to antipsychotic treatment. For participants with clinically significant hallucinations, the symptom had decreased to “mild” according to PANSS P3 after 3 weeks and continued to decrease throughout the follow-up period. This finding is consistent with our previous findings, where 80% of patients with clinically significant hallucinations at baseline were found to be “dramatic” responders, with extinction of hallucinations during the first 4 weeks of treatment.11 The present results are also in line with findings from Sommer et al10 where first-episode schizophrenia patients showed a mean reduction of hallucinations from 4.4 at baseline to 2.5 after 4 weeks of treatment measured by the PANSS P3.

Most studies investigating drug differences have used the total psychopathology score from the PANSS questionnaire or symptom clusters as outcome measures. The meta-analysis by Huhn et al6 reveals gradual differences in effect sizes when comparing 32 antipsychotic drugs in multiphase schizophrenia patients. The results showed that both amisulpride and olanzapine were among the most efficacious antipsychotics, whereas aripiprazole seemed to be less effective. However, a meta-analysis by Rutherford et al25 showed that over time, there was a placebo-effect increase, together with an active medication-effect decrease. Thus, the smaller effect of aripiprazole compared with the 2 other antipsychotics in the meta-analysis may be at least in part explained by the fact that the aripiprazole studies have been conducted in more recent years.

None of the studies included in the meta-analysis by Huhn et al6 focused on hallucinations specifically. However, Sommer et al10 used data from the EUFEST trial where first-episode psychosis (FEP) patients were followed up for 1 year. The authors found that all the included atypical antipsychotics were equally effective against hallucinations, but haloperidol was slightly inferior. Almost half of our sample was AP− at inclusion, which may be considered a proxy for FEP. When analyzing this subgroup separately, no statistically significant differences were found among the study drugs. Thus, our study contributes to existing evidence that the antihallucinatory effectiveness among atypical antipsychotics for the subgroup of patients in an early stage of psychosis may be equal. A possible explanation may be that in this particular group, “everything works” because they are generally highly responsive to antipsychotic medication, whereas in multiphase patients, where the drug response generally is poorer, probably also because the proportion of patients with more severe disorder is higher, the separate drugs are subject to a tougher test. Thus, differences in the effectiveness of antipsychotic drugs may appear. A previous study from our group has also shown that ziprasidone and quetiapine were superior to risperidone in reducing hallucinations, with olanzapine in an intermediate position. In this randomized controlled trial, patients were followed up for up to 2 years.12 In the present study, olanzapine was less effective for reduction of hallucinations compared with amisulpride and, at some time points, also less effective compared with aripiprazole. This finding seems to be driven by the participants previously exposed to antipsychotics, as statistically significant differences were only seen in the AP+ subgroup.

Olanzapine is generally found to be among the most efficacious drugs,4 so the reduced effect compared with the other 2 study drugs in participants previously treated with antipsychotics was unexpected. However, as discussed previously, most of the antipsychotic studies have measured the effect or effectiveness of drug treatment on PANSS total psychopathology or total subscale scores. Thus, it is possible that the effect of olanzapine seen in other studies may be primarily the result of an effect on other positive symptoms than hallucinations. For example, delusions are assessed in 3 of 7 items in the PANSS positive subscale, whereas hallucinations are assessed in only 1. Accordingly, the weight of any change of hallucinations may theoretically be buried under changes of delusions.

A mechanistic explanation for the inferiority of effect for olanzapine compared with amisulpride and aripiprazole in the AP+ subgroup could be related to differences in prefrontal cortex activation. It is suggested in the neurocognitive model of hallucinations26 that this is the result of unbalanced hyperactivation in the temporal lobe not sufficiently inhibited by frontotemporal projections because of prefrontal hypoactivation. Limited evidence also shows that both amisulpride and aripiprazole activate prefrontal cortex, whereas for olanzapine, the results are more conflicting.27,28 Olanzapine impairs some cognitive functions; thus, possibly prefrontal cortical activation may be low because of its sedating effects via blockade of muscarinicergic, histaminergic, and adrenergic receptors. If the antihallucinatory response partly depends on activation of prefrontal cortex, then differential prefrontal cortical impairment could hypothetically contribute to the superiority of amisulpride and aripiprazole over olanzapine. Because cognitive activation is found to be reduced in more chronic patients and because the difference among antipsychotics appears only in AP+ participants, it could suggest that prefrontal activity is more sensitive to antipsychotics only in patients with reduced prefrontal cortex activity.
Limitations

Some limitations should be mentioned. The pragmatic design of the study allows for fewer exclusion criteria, thus possibly resulting in a more heterogeneous sample. However, such a study design mimics “real life,” and the results can therefore be interpreted in the light of a daily clinical setting. The decision to allow for the change of antipsychotic treatment regime over the course of the study may have affected our results. However, the small number of participants who changed treatment regime makes this a less likely possibility. A high attrition rate is also a concern, which is a major problem in all antipsychotic trials. A sensitivity analysis showed that using the missing-at-random assumption in the statistical analyses is plausible, both for the total sample and for the HALL subgroup. Total attrition was not associated with any of the demographic variables and did not exceed the rate found in other studies. Use of concomitant drugs might be considered as a limitation. However, there were generally no differences among the groups, and it was not considered to influence the results.

Our choice to include in the main analyses participants with P3 score ≤3 might be seen as a limitation because a score of 3 is considered below the psychosis threshold. However, a score of 3 in the PANS scoring manual is described as “hallucinations or abnormal perceptual experiences that does not affect thinking or behavior,” so even at subthreshold levels for psychosis, a score of 3 remains a symptom frequently present in psychotic populations. Considering that subpsychosis levels of symptoms have shown brain activation in functional magnetic resonance imaging studies, this threshold was chosen to better capture potential differences of antipsychotics, which theoretically would act partly via different neurotransmitter systems. However, we conducted sensitivity analyses in addition, where participants with P3 ≥4 were included. Interestingly, similar result was present when olanzapine showed less reduction for hallucinations in participants previously treated with antipsychotics, mainly when compared with amisulpride.

We did not correct for multiple comparisons, which might increase the chance for false-positive results. However, the statistical significant results seemed to follow an internally consistent pattern throughout the study up to 52 weeks and were therefore by far more common and consistent than would have been expected to occur by chance.

Despite the relatively large number of participants and direct comparison of antipsychotics, our results should be interpreted with caution before independently replicated.

Conclusions

Hallucinations respond fairly well to antipsychotics. Differential antihallucinatory effectiveness was found for the 3 study drugs, but this was seen only in participants exposed to antipsychotic treatment before entering the study, whereas no significant differences were found for the AP–participants.

REFERENCES

1. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008; 100:20–38.

2. Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201:481–485.

3. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:959–951.

4. McCutcheon RA, Pillinger T, Mizuno Y, et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis [published online August 30, 2019]. Mol Psychiatry. doi:10.1038/s41380-019-0502-5.

5. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15–33.

6. Hugdahl K. Auditory hallucinations: a review of the ERC “VOICE” project. World J Psychiatry. 2015;5:193–209.

7. McCarthy-Jones S, Smailes D, Crovian A, et al. Occurrence and co-occurrence of hallucinations by modality in schizophrenia-spectrum disorders. Psychiatry Res. 2017;252:154–160.

8. Kjelby E, Sinkevičiute I, Gjestad R, et al. Suicidality in schizophrenia spectrum disorders: the relationship to hallucinations and persecutory delusions. Eur Psychiatry. 2015;30:830–836.

9. Dugre JR, West ML. Disentangling compliance with command hallucinations: heterogeneity of voice intents and their clinical correlates. Schizophr Res. 2019;212:33–39.

10. Sommer IE, Slotema CW, Daskalakis ZJ, et al. The treatment of hallucinations in schizophrenia spectrum disorders. Schizophr Bull. 2012; 38:704–714.

11. Sinkevičiute I, Gjestad R, Kjelby E, et al. Trajectories of treatment response in hallucinations. Neuropsychiatry (London). 2019;9:2198–2206.

12. Johnsen E, Sinkevičiute I, Loberg EM, et al. Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study. BMC Psychiatry. 2013;13:241.

13. Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20–41.

14. Zhu Y, Li C, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27:835–844.

15. Jager M, Riedel M, Messer T, et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci. 2007; 257:47–53.

16. Johnsen E, Kroken RA, Loberg EM, et al. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. Lancet Psychiatry. 2020; 7:945–954.

17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.

18. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Available at: http://apps.who.int/classifications/icd10/browse/2010/en. Accessed November 23, 2019.

19. Mueser KT, Drake RE, Clark RE, et al. Toolkit for Evaluating Substance Abuse in Persons With Severe Mental Illness. Cambridge, MA: Evaluation Center, Human Services Research Institute; 1995.

20. Lindstrom E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55(suppl 44):5–69.

21. Guy W. ECDEU Assessment Manual for Psychopharmacology: Rockville, MD: Department of Health, Education, and Welfare; 1976.

22. Kartenud S, Pedersen G, Loevdahl H, et al. Global Assessment of Functioning—Split Version (S-GAF): background and scoring manual. Available at: https://oslo-universitetssykehus.no/aksjon/nasjonalkompetansetjeneste-for-personlighetpsykiatri-napp/Documents/S-GAF% 20veiledning.pdf. Accessed June 22, 2018.
23. The R Foundation. The R Project for Statistical Computing. Available at: https://www.r-project.org/. Accessed November 25, 2020.

24. Harrison XA, Donaldson L, Correa-Cano ME, et al. A brief introduction to mixed effects modelling and multi-model inference in ecology. PeerJ. 2018;6:e4794.

25. Rutherford BR, Pott E, Tandler JM, et al. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiat. 2014;71:1409–1421.

26. Hugdahl K. “Hearing voices”: auditory hallucinations as failure of top-down control of bottom-up perceptual processes. Scand J Psychol. 2009;50:553–560.

27. Vaiva G, Thomas P, Llorca PM, et al. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res. 2002;115:37–48.

28. Schlagenhauf F, Dinges M, Beck A, et al. Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation. Schizophr Res. 2010;118:189–200.

29. Gonul AS, Kula M, Sofuoglu S, et al. Te-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2003;253:29–33.

30. Blasi G, Popolizio T, Taurisano P, et al. Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia. Psychiatry Res. 2009;173:31–38.

31. Buchsbaum MS, Haznedar MM, Aronowitz J, et al. FDG-PET in never- previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophr Res. 2007;94:293–305.

32. Wahlbeck K, Tuunainen A, Ahokas A, et al. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl). 2001;155:230–233.